Flexible dosing strategy tested in fight against advanced kidney cancer
NCT ID NCT06860386
Summary
This study is testing whether a flexible, 'adaptive' dosing schedule for a two-drug combination is a practical approach to treat advanced kidney cancer. It will involve about 75 adults with a specific type of kidney cancer who have not yet received any treatment for their advanced disease. The main goals are to see if enough eligible patients agree to this approach and to measure how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.